Implantica prepares Module 2 submission of PMA application to FDA for RefluxStop
Implantica has announces finalisation of the five-year CE mark study results as part of the upcoming Module 2 submission (of 3 modules)...
top of page
Browse by category
Search
RefluxStop provides substantial clinical benefits for GERD patients with marginal budget impact on the health service
Introducing RefluxStop device (Implantica) as a treatment option for gastroesophageal reflux disease (GERD) patients treated within the...
First RefluxStop procedures performed in Italy
Implantica has announced that the first RefluxStop procedures to treat acid reflux have been performed in Italy, a key market where more...
Implantica launches RefluxStop in Spain
Implantica has announced that the first two RefluxStop procedures to treat acid reflux have been performed at the Hospital Universitario...
Browse by tag
bottom of page